Nothing Special   »   [go: up one dir, main page]

KR950008537A - Diagnostic Agents for Detection of Antibodies Against Epstein Bacillus (EBV) - Google Patents

Diagnostic Agents for Detection of Antibodies Against Epstein Bacillus (EBV) Download PDF

Info

Publication number
KR950008537A
KR950008537A KR1019940022989A KR19940022989A KR950008537A KR 950008537 A KR950008537 A KR 950008537A KR 1019940022989 A KR1019940022989 A KR 1019940022989A KR 19940022989 A KR19940022989 A KR 19940022989A KR 950008537 A KR950008537 A KR 950008537A
Authority
KR
South Korea
Prior art keywords
protein
diagnostic agent
seq
vca
ebna
Prior art date
Application number
KR1019940022989A
Other languages
Korean (ko)
Other versions
KR100378942B1 (en
Inventor
야프 미킬 미델도르프
보우테루스 마리누스 요하네스 판 그룬스펜
Original Assignee
에프. 게. 엠. 헤르만스, 페. 카. 브론스
악조 노벨 엔. 브이.
페.카.브론스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 게. 엠. 헤르만스, 페. 카. 브론스, 악조 노벨 엔. 브이., 페.카.브론스 filed Critical 에프. 게. 엠. 헤르만스, 페. 카. 브론스
Publication of KR950008537A publication Critical patent/KR950008537A/en
Application granted granted Critical
Publication of KR100378942B1 publication Critical patent/KR100378942B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is directed to diagnostic reagents for the detection of antibodies against the Epstein Barr Virus and a method for the detection of antibodies to the Epstein Barr Virus in a sample. The diagnostic reagents according to the invention comprise a combination of at least part of an Epstein Barr viral structural protein, preferably a Epstein Barr VCA-protein or an Epstein Barr MA protein, and at least part of an Epstein Barr EBNA protein. Preferably, the VCA-protein is VCA-p18 protein, the MA-protein is MA-gp350/220 protein and the EBNA-protein is EBNA-1 protein. It has been found that the combination of a VCA-protein or a MA-protein, and an EBNA protein, into a single diagnostic assay yields an EBV-antibody detection method with greater sensitivity and accuracy than current methods.

Description

엡스타인 바 비류스(EBV)에 대한 항체의 검출용 진단제Diagnostic Agents for Detection of Antibodies Against Epstein Barbies (EBV)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 비루스 생산 세포주 P3HR1-HH514-C16에서 발현되는 EBV-단백질(EBNA+VCA)과 혈청 IgG의 반응성에 대해 시험한 무작위 수집한 건강한 혈액공여자 샘플의 면역블로트 분석을 도시한 것이다.FIG. 1 depicts immunoblot analysis of randomly collected healthy blood donor samples tested for reactivity of EBV-protein (EBNA + VCA) and serum IgG expressed in virus producing cell line P 3 HR 1 -HH514-C16. .

제2도는 VCA-p18 및 EBNA-1의 각각 및 혼합물에 대한 IgG-반응성에 대한 인체 혈청 샘플의 Elisa반응성(450nm에서의 광학 밀도)을 도시한 것이다.2 shows Elisa reactivity (optical density at 450 nm) of human serum samples to IgG-response to each and mixtures of VCA-p18 and EBNA-1.

Claims (14)

엡스타인 바 비루스에 대한 항체의 검출용 진단체에 있어서, 상기 진단체는 적어도 일부분의 엡스타인 바 비루스 구조 단백질과 적어도 일부분의 엡스타인 바 EBNA단백질의 혼합물을 포함함을 특징으로 하는 진단제.A diagnostic agent for the detection of an antibody against Epstein Barbies, wherein the diagnostic agent comprises a mixture of at least a portion of an Epstein Barbies structural protein and at least a portion of an Epstein Barr EBNA protein. 제1항에 있어서, 비루스 구조 단백질은 MA-단백질임을 특징으로 하는 진단제.The diagnostic agent of claim 1, wherein the viral structural protein is a MA-protein. 제2항에 있어서, MA-단백질이 MA-gp350/220단백질임을 특징으로 하는 진단제.The diagnostic agent according to claim 2, wherein the MA-protein is MA-gp350 / 220 protein. 제1항에 있어서, 비루스 구조 단백질이 VCA-단백질임을 특징으로 하는 진단제.The diagnostic agent according to claim 1, wherein the virus structural protein is a VCA-protein. 제4항에 있어서, VCA-단백질이 VCA-p18단백질임을 특징으로 하는 진단제.The diagnostic agent according to claim 4, wherein the VCA-protein is VCA-p18 protein. 제5항에 있어서, 진단제는 서열 동정 번호 1에 도시한 아미노산 서열의 적어도 일부분을 포함하는 펩티드를 포함함을 특징으로 하는 진단제.6. The diagnostic agent of claim 5, wherein the diagnostic agent comprises a peptide comprising at least a portion of the amino acid sequence shown in SEQ ID NO: 1. 제6항에 있어서, 펩티드는 서열 동정 번호 2, 3또는 4에 도시한 아미노산 서열을 포함함을 특징으로 하는 진단제.The diagnostic agent according to claim 6, wherein the peptide comprises the amino acid sequence shown in SEQ ID NO: 2, 3 or 4. 제1항 내지 제7항 중 어느 한 항에 있어서, EBNA 단백질이 EBNA-1단백질임을 특징으로 하는 진단제.The diagnostic agent according to any one of claims 1 to 7, wherein the EBNA protein is an EBNA-1 protein. 제8항에 있어서, 진단제는 서열 동정 번호 5에 도시한 아미노산 서열의 적어도 일부분을 포함하는 펩티드를 포함함을 특징으로 하는 진단제.The diagnostic agent of claim 8, wherein the diagnostic agent comprises a peptide comprising at least a portion of the amino acid sequence shown in SEQ ID NO: 5. 제9항에 있어서, 펩티드는 서열 동정 번호 6, 7, 8 또는 9에 도시된 아미노산 서열을 포함함을 특징으로 하는 진단제.10. The diagnostic agent of claim 9, wherein the peptide comprises the amino acid sequence shown in SEQ ID NO: 6, 7, 8, or 9. 제4항에 있어서, 서열 동정 번호 4에 도시된 아미노산 서열을 갖는 펩티드 및 서열 동정 번호 9에 도시된 아미노산 서열을 갖는 펩티드를 포함하는 진단제.The diagnostic agent according to claim 4, comprising a peptide having an amino acid sequence shown in SEQ ID NO: 4 and a peptide having an amino acid sequence shown in SEQ ID NO: 9. 제3항에 있어서, 진단제는 서열 동정 번호9에 도시된 아미노산 서열을 갖는 펩티드를 포함함을 특징으로 하는 진단제.4. The diagnostic agent of claim 3, wherein the diagnostic agent comprises a peptide having the amino acid sequence shown in SEQ ID NO: 9. 샘플내에서 엡스타인 바 비루스에 대한 항체를 검출하는 방법에 있어서, 상기 샘플은 제1항 내지 제12항 중 어느 한 항에 따른 진단제와 접촉되며 상기 진단제와 항체 사이에서 형성된 면역 복합체가 검출됨을 특징으로 하는 검사 키트.13. A method for detecting an antibody against Epstein barvirus in a sample, wherein the sample is contacted with a diagnostic agent according to any one of claims 1 to 12 and the immune complex formed between the diagnostic agent and the antibody is detected. Characterized by the test kit. 샘플내에서 엡스타인 바 비루스에 대한 항체를 검출하는 검사키트에 있어서, 상기 검사키트는 제1항 내지 제12항중 어느 한 항에 따른 진단제를 포함함을 특징으로 하는 검사 키트.A test kit for detecting an antibody against Epstein barvirus in a sample, wherein the test kit comprises a diagnostic agent according to any one of claims 1 to 12. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940022989A 1993-09-14 1994-09-13 Diagnostic reagents for detection of antibodies against Epstein-Barbitus (EBV) KR100378942B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93202659 1993-09-14
EP93202659.4 1993-09-14

Publications (2)

Publication Number Publication Date
KR950008537A true KR950008537A (en) 1995-04-19
KR100378942B1 KR100378942B1 (en) 2003-05-22

Family

ID=8214091

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940022989A KR100378942B1 (en) 1993-09-14 1994-09-13 Diagnostic reagents for detection of antibodies against Epstein-Barbitus (EBV)

Country Status (13)

Country Link
US (1) US5827646A (en)
EP (1) EP0649904B1 (en)
JP (1) JP3547493B2 (en)
KR (1) KR100378942B1 (en)
AT (1) ATE231556T1 (en)
AU (1) AU679545B2 (en)
CA (1) CA2131874C (en)
DE (1) DE69432043T2 (en)
DK (1) DK0649904T3 (en)
ES (1) ES2191673T3 (en)
FI (1) FI113298B (en)
HK (1) HK1001222A1 (en)
ZA (1) ZA947061B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2765688B1 (en) * 1997-07-04 1999-09-10 Pasteur Institut REAGENT FOR DETECTION AND MONITORING OF INFECTIONS CAUSED BY THE EPSTEIN-BARR VIRUS AND ITS APPLICATIONS
DE10307517A1 (en) * 2003-02-21 2004-09-02 Mikrogen Molekularbiologische Entwicklungs-Gmbh Peptides derived from capsid antigens of the Epstein-Barr virus and their use
WO2006098804A2 (en) 2005-03-11 2006-09-21 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
EP1908828A1 (en) * 2005-07-22 2008-04-09 PHG Corporation Novel polypeptide and method for producing the same
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
US7628150B2 (en) * 2007-08-17 2009-12-08 Vladimir Malkov Versatile flexible mat and method of implementing and using same
US20100022916A1 (en) 2008-07-24 2010-01-28 Javanbakhsh Esfandiari Method and Apparatus for Collecting and Preparing Biological Samples for Testing
US8603835B2 (en) 2011-02-10 2013-12-10 Chembio Diagnostic Systems, Inc. Reduced step dual path immunoassay device and method
KR101678553B1 (en) 2012-04-30 2016-11-22 (주)바이오니아 Oligonucleotide kit for detecting Epstein-Bar virus and EBV detecting methods using the same
WO2014025254A1 (en) 2012-08-10 2014-02-13 Stichting Vu-Vumc Ebv markers and systemic lupus erythematosus
EP3126486B1 (en) 2014-04-02 2019-07-03 Chembio Diagnostic Systems, Inc. Immunoassay utilizing trapping conjugate
US20160116466A1 (en) 2014-10-27 2016-04-28 Chembio Diagnostic Systems, Inc. Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses
CN106645715B (en) * 2016-11-18 2018-11-23 安徽医科大学 It is a kind of for the protein-chip of 1 protein antibodies joint-detection of Epstein-Barr virus capsid antigen and nuclear antigen and its preparation and application
CN108490177B (en) * 2018-02-08 2020-12-29 深圳市新产业生物医学工程股份有限公司 Nasopharyngeal carcinoma antibody detection reagent, preparation method thereof and nasopharyngeal carcinoma detection kit
CN111548411B (en) * 2020-04-30 2022-03-29 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Monoclonal antibody for neutralizing EB virus and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116725A (en) * 1984-08-08 1992-05-26 Scripps Clinic And Research Foundation Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides
JPH04310861A (en) * 1991-04-09 1992-11-02 Kazuo Yanagi Method and kit for measuring anti-ebna antibody
DK1225226T3 (en) * 1992-03-13 2008-04-14 Biomerieux Bv Peptides and nucleic acid sequences related to Epstein-Barr virus

Also Published As

Publication number Publication date
EP0649904B1 (en) 2003-01-22
FI113298B (en) 2004-03-31
AU7295694A (en) 1995-03-30
DE69432043D1 (en) 2003-02-27
CA2131874C (en) 2006-03-28
HK1001222A1 (en) 1998-06-05
FI944225A0 (en) 1994-09-13
DK0649904T3 (en) 2003-04-22
CA2131874A1 (en) 1995-03-15
KR100378942B1 (en) 2003-05-22
FI944225A (en) 1995-03-15
JPH07209302A (en) 1995-08-11
AU679545B2 (en) 1997-07-03
ZA947061B (en) 1995-04-27
JP3547493B2 (en) 2004-07-28
US5827646A (en) 1998-10-27
EP0649904A1 (en) 1995-04-26
ES2191673T3 (en) 2003-09-16
ATE231556T1 (en) 2003-02-15
DE69432043T2 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
KR950008537A (en) Diagnostic Agents for Detection of Antibodies Against Epstein Bacillus (EBV)
Saxinger et al. Application of the indirect enzyme-linked immunosorbent assay microtest to the detection and surveillance of human T cell leukemia-lymphoma virus.
Towbin et al. Immunoblotting in the clinical laboratory
DE3485299D1 (en) DETECTION OF ANTIGENT ACTIVE AMINO ACID SEQUENCES.
BR9809443A (en) Polypeptide comprising an antigenic portion of an antigen of m. tuberculosis, dna molecule, recombinant expression vector, host cell, process for detection of m. tuberculosis in a biological sample, diagnostic kit, monoclonal antibody, polyclonal antibody, and fusion protein.
ATE127517T1 (en) METHODS AND PRODUCTS FOR DETECTING HUMAN T-CELL LEUKEMIA VIRUS.
ES2080099T3 (en) TEST FOR HEPATITIS C.
BR9712298A (en) Polypeptide, DNA molecule, recombinant expression vector, host cell, process to detect infection by m. tuberculosis in a biological sample, diagnostic kit, monoclonal, and, polyclonal, and, fusion protein
EP1318401A3 (en) Method for the early detection of the seroconversion of an anti hepatitis C virus antibody
DE69131579D1 (en) SYNTHETIC ANTIGING OF AN AGING CELL
ES2145746T3 (en) DETECTION ANALYSIS OF HEPATITIS C.
SE8900721D0 (en) METHODS FOR DETECTION OF ANTIBODIES TO
ES2159291T3 (en) METHOD AND ANALYSIS OF HTLV-I / HTLV-II.
KR880014376A (en) Monoclonal Antibodies of the HIV Specific Antigen Region and Their Uses
KR940005666A (en) Antigenic peptides for classifying hepatitis C virus, kits comprising the peptide and methods of classifying hepatitis C virus using the peptide
US20030108563A1 (en) Reagents for the simultaneous detection of HCV core antigens and antibodies
NO913037L (en) PEPTIDES WITH ALFAL MICROGLOBULIN CHARACTERISTIC ANTIGEN DETERMINANTS.
ATE143142T1 (en) IMMUNOASSAY FOR DETECTING ANTIBODIES AGAINST HIV
Ritter et al. Autoantibodies against triosephosphate isomerase. A possible clue to pathogenesis of hemolytic anemia in infectious mononucleosis.
McArthur et al. A rapid micro-method for screening eel sera for antibodies against the digenean Telogaster opisthorchis Macfarlane, 1945.
KR910007962A (en) HIV related peptides
FI102381B1 (en) Synthetic polypeptides associated with Epstein-Barr virus nuclear antigen (EBNA) and method for identifying anti-EBNA antibodies in a tissue sample
Oliver et al. Autoantibodies to the cytoskeleton in human sera
KR930007970A (en) Non-A, Non-Type Peptides
Cranage et al. An indirect haemadsorption procedure (MRSPAH) for detecting antibodies to respiratory syncytial virus

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130311

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20140311

Year of fee payment: 12

EXPY Expiration of term